Breakthrough Alzheimer's Drug Slows Disease Progression and Offers Hope for Patients

Results from an 18-month trial led by Eli Lilly have shown that the Alzheimer's drug donanemab can delay the progression of the disease by up to 35.1 percent, with certain patients experiencing a slowdown of 4.4 to 7.5 months. The drug is expected to be approved by the FDA, making it the third medication available for Alzheimer's treatment in the US. However, the trial also revealed severe side effects, including brain bleeds and swelling, primarily affecting those in the early stages of the disease. The study's limitations, such as a predominantly White participant group and a restricted age range, highlight the need for further research to determine the drug's efficacy and potential side effects.